List of Sprycel drug patents
Sprycel is owned by Bristol Myers Squibb.
Sprycel contains Dasatinib.
Sprycel has a total of 4 drug patents out of which 0 drug patents have expired.
Sprycel was authorised for market use on 28 June, 2006.
Sprycel is available in tablet;oral dosage forms.
The generics of Sprycel are possible to be released after 28 September, 2026.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7491725 | BRISTOL MYERS SQUIBB | Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors |
Mar, 2026
(2 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8680103 | BRISTOL MYERS SQUIBB | Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors |
Feb, 2025
(1 year, 10 months from now) | |
|
US8680103
(Pediatric) | BRISTOL MYERS SQUIBB | Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors |
Aug, 2025
(2 years from now) | |
|
US7491725
(Pediatric) | BRISTOL MYERS SQUIBB | Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors |
Sep, 2026
(3 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Dec 21, 2025 |
| Pediatric Exclusivity (PED) | May 9, 2025 |
Drugs and Companies using DASATINIB ingredient
Market Authorisation Date: 28 June, 2006
Treatment: NA
Dosage: TABLET;ORAL
SPRYCEL family patents
14
United States
3
Korea, Republic of
3
Japan
2
Australia
2
Russia
2
Norway
2
Argentina
2
Brazil
2
Taiwan, Province of China
2
Canada
2
European Union
1
Israel
1
South Africa
1
Denmark
1
Austria
1
Mexico
1
Hong Kong
1
Slovenia
1
Germany
1
Croatia
1
Portugal
1
Cyprus
1
Spain
1
Peru
1
Poland
1
India
1
China
1
Georgia
1
New Zealand
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic